CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients

Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients

(2013) Leszek Pączek   Annals of Transplantation

Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks

(2013) Laure Elens et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation

(2013) Dennis A. Hesselink et al.   CLINICAL PHARMACOKINETICS

Associations of ABCB1 3435C>T and IL-10-1082G>A Polymorphisms With Long-Term Sirolimus Dose Requirements in Renal Transplant Patients

(2011) Wai-Johnn Sam et al.   TRANSPLANTATION

Influence of CYP3A5 and MDR1(ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Chinese Renal Transplant Recipients

(2010) G. Rong et al.   TRANSPLANTATION PROCEEDINGS

Genetic Polymorphisms and Individualized Tacrolimus Dosing

(2010) M.A. López-Montenegro Soria et al.   TRANSPLANTATION PROCEEDINGS

Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India

(2009) Ranjana Singh et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY